Q2 EPS Forecast for Revolution Medicines Lowered by Analyst

Key Points

• Lifesci Capital lowered its Q2 2026 EPS estimate for Revolution Medicines to ($1.90) from ($1.85), while also projecting continued losses through 2026 and 2027. The consensus full-year 2026 estimate remains a loss of ($7.59) per share.
• The company just reported a wider-than-expected Q1 loss, posting ($2.29) EPS versus estimates of ($1.83). That was also a bigger loss than the prior year’s ($1.13) per share.
• Sentiment around RVMD remains broadly positive despite losses, with several firms raising price targets and the stock carrying a consensus Buy rating and an average target price of $103.88. Recent clinical updates on its pancreatic cancer program also appear to be supporting optimism.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Research analysts at Lifesci Capital dropped their Q2 2026 earnings per share estimates for Revolution Medicines in a report issued on Wednesday, May 6th. Lifesci Capital analyst C. Zhu now anticipates that the company will post earnings per share of ($1.90) for the quarter, down from their prior estimate of ($1.85). The consensus estimate for Revolution Medicines' current full-year earnings is ($7.59) per share. Lifesci Capital also issued estimates for Revolution Medicines' Q3 2026 earnings at ($1.97) EPS, Q4 2026 earnings at ($1.92) EPS, FY2026 earnings at ($8.06) EPS and FY2027 earnings at ($10.74) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.83) by ($0.46). During the same period in the prior year, the company posted ($1.13) earnings per share.

A number of other brokerages have also recently issued reports on RVMD. Wedbush boosted their price objective on Revolution Medicines to $165.00 and gave the stock an "outperform" rating in a report on Thursday. Benchmark reiterated an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Piper Sandler lifted their price target on shares of Revolution Medicines to $172.00 and gave the company an "overweight" rating in a research report on Thursday. Jefferies Financial Group began coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a "buy" rating for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $103.88.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $141.81 on Monday. Revolution Medicines has a 12-month low of $34.00 and a 12-month high of $155.70. The stock has a market cap of $30.15 billion, a PE ratio of -20.06 and a beta of 1.41. The business has a 50 day moving average of $113.41 and a 200-day moving average of $94.43. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC lifted its stake in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock worth $32,000 after purchasing an additional 361 shares during the last quarter. Indiana Trust & Investment Management Co bought a new stake in Revolution Medicines during the fourth quarter worth $32,000. Torren Management LLC bought a new stake in Revolution Medicines during the fourth quarter worth $33,000. Arax Advisory Partners bought a new stake in Revolution Medicines during the fourth quarter worth $38,000. Finally, Darwin Wealth Management LLC bought a new stake in Revolution Medicines during the fourth quarter worth $40,000. 94.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Xiaolin Wang sold 2,010 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares in the company, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Michael Kelsey sold 4,302 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the completion of the sale, the insider owned 295,398 shares of the company's stock, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 184,592 shares of company stock valued at $24,499,532 in the last quarter. Corporate insiders own 8.20% of the company's stock.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Piper Sandler raised its price target on Revolution Medicines to $172 and reiterated an overweight view, adding to recent bullish calls from other firms and reinforcing confidence in the company’s growth outlook. Revolution Medicines NASDAQ: RVMD Price Target Raised to $172.00 at Piper Sandler
• Positive Sentiment: Revolution Medicines announced publication of Phase 1/2 daraxonrasib data in the New England Journal of Medicine, strengthening the scientific case for its pivotal RASolute 302 pancreatic cancer trial. Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
• Positive Sentiment: Reuters reported that the company’s experimental pancreatic cancer drug showed a strong survival benefit in trials, which could boost confidence in RVMD’s lead program and long-term pipeline value. Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
• Neutral Sentiment: Q1 earnings showed a wider-than-expected loss and the company raised its 2026 expense outlook, underscoring that RVMD is still investing heavily in R&D and commercial preparation. RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
• Neutral Sentiment: TipRanks highlighted a new warrant-related risk ahead of the 2026 expiry, noting possible dilution concerns and the possibility that the warrants could expire worthless, which adds a layer of uncertainty for shareholders. Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
• Negative Sentiment: Despite the clinical progress, higher losses and rising spending could weigh on sentiment if investors focus on the company’s need for continued funding before any product revenue arrives. Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.